Sugi Predict

Sugi Predict / Compounds / SCHEMBL202945

SCHEMBL202945

SCHEMBL202945

COc1ccc(F)c(C(N)=O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP10 Q53GL7 4/20 0.50
▸ KDM4E B2RXH2 2/20 0.50
▸ PARP1 P09874 2/20 0.50
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50
▸ PARP2 Q9UGN5 1/20 0.50
▸ PARP4 Q9UKK3 1/20 0.50
▸ CPS1 P31327 3/20 0.49
▸ MAPT P10636 2/20 0.48
▸ HTT P42858 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ PARP15 Q460N3 1/20 0.46
▸ PARP14 Q460N5 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL72082 0.85 CPS1 (0.61) PARP10KDM4EPARP1CA1CA2
Hydrazine SCHEMBL28177126 0.84 SMN1; SMN2 (0.56) KDM4ECPS1MAPTSMN1; SMN2ALDH1A1
SCHEMBL31741591 0.83 ALDH1A1 (0.59) KDM4ECPS1MAPTHTTNPSR1
SCHEMBL395640 0.83 SMN1; SMN2 (0.59) KDM4ECA1CA2CPS1MAPT
SCHEMBL5196960 0.83 ALDH1A1 (0.59) KDM4ECPS1MAPTHTTNPSR1
SCHEMBL2835948 0.82 PARP1 (0.55) PARP10KDM4EPARP1CA1CA2
SCHEMBL2258923 0.81 KDM4E (0.60) KDM4ECA1CA2CPS1MAPT
SCHEMBL2551429 0.81 PRSS1 (0.50) KDM4ECA1CA2CPS1MAPT
SCHEMBL24338 0.81 CPS1 (0.49) CPS1MAPTHTTNPSR1NPC1
SCHEMBL25213585 0.81 CA1 (0.54) KDM4ECA1CA2MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570645-B2 Uses of p53 x-ray co-crystal structures PMV PHARMACEUTICALS, INC. (US) 2026-03-10 — — US disclosed
US-20260027097-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS INC (US) 2026-01-29 — — US disclosed
US-20250319063-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV PHARMACEUTICALS, INC. 2025-10-16 — — US disclosed
US-12419880-B2 Companion diagnostic tool for mutant p53 reactivating compounds PMV PHARMACEUTICALS, INC. (US) 2025-09-23 — — US disclosed
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 — — US disclosed
CN-119790057-A Novel PLK1 degradation inducing compounds 厄普特拉株式会社 2025-04-08 — — CN disclosed
CN-119161345-A Tetrahydropteridinone derivatives as selective covalent inhibitors of Plk1 kinase 润药仁智(北京)科技有限公司 2024-12-20 — — CN disclosed
CN-116322700-B Novel PLK1 degradation inducing compounds 厄普特拉株式会社 2024-08-20 — — CN disclosed
US-20240269126-A1 COMBINATION THERAPY FOR TREATMENT OF CANCER PMV PHARMACEUTICALS, INC. 2024-08-15 — — US disclosed
CN-118076607-A Novel PLK1 degradation inducing compounds 厄普特拉株式会社 2024-05-24 — — CN disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 — — WO disclosed
US-5656657-A Chroman derivatives ASTRA AKTIEBOLAG (SE) 1997-08-12 — — US disclosed
US-5656658-A Method for the treatment of anxiety ASTRA AKTIEBOLAG (SE) 1997-08-12 — — US disclosed
US-5650524-A Process for preparing (R)-3-amino-5-methoxychroman ASTRA AKTIEBOLAG (SE) 1997-07-22 — — US disclosed
US-5646309-A Intermediates in the synthesis of chroman derivatives ASTRA AKTIEBOLAG (SE) 1997-07-08 — — US disclosed
US-5641807-A Method for the treatment of depression ASTRA AKTIEBOLAG (SE) 1997-06-24 — — US disclosed
US-5639772-A Chroman derivatives ASTRA AKTIEBOLAG (SE) 1997-06-17 — — US disclosed
US-5639784-A ADMINISTERING 3-AMINO-5-CARBAMOYL-CHROMENES AND DERIVATIVES ASTRA AKTIEBOLAG (SE) 1997-06-17 — — US disclosed
US-5500425-A Chroman derivatives and a method of treating 5-HT mediated disorders AKTIEBOLAGET ASTRA (SE) 1996-03-19 — — US disclosed
US-5420151-A Chroman derivatives AKTIEBOLAGET ASTRA (SE) 1995-05-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250319063-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION TP53, TP53BP1, KRAS PARP10 1556/4885KDM4E 3022/4885PARP1 865/4885
US-20260027097-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, BRCA1 PARP10 2388/4885KDM4E 385/4885PARP1 457/4885
US-12570645-B2 Uses of p53 x-ray co-crystal structures TP53, TP53BP1, ERCC2 PARP10 873/4885KDM4E 3295/4885PARP1 694/4885
US-20240269126-A1 COMBINATION THERAPY FOR TREATMENT OF CANCER TP53, KRAS, TP53BP1 PARP10 1065/4885KDM4E 3164/4885PARP1 457/4885
US-12419880-B2 Companion diagnostic tool for mutant p53 reactivating compounds TP53, TP53BP1, KRAS PARP10 927/4885KDM4E 3177/4885PARP1 928/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 PARP10 3006/4885KDM4E 2407/4885PARP1 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.